Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, has operationalised the first phase of its biologics manufacturing facility in Bengaluru, through its 100% subsidiary, Aragen Biologics.
The facility is being set up at an investment of $30 million. It has also executed its first small-scale manufacturing project for a US-based organisation for manufacturing a novel anticancer monoclonal antibody (mAb). The non-GMP facility can undertake batch sizes upto 50 Ltrs and includes process development and analytical labs to support the manufacturing activities.
Manni Kantipudi, CEO, Aragen Life Sciences and Director of Aragen Biologics said, “Once the facility’s expansion is fully operational by the end of this calendar year, we will be able to do internal tech transfer from our R&D labs in California to the manufacturing site in India, thereby enabling end-to-end integrated service offering to customers.”
Aragen currently offers discovery and development research services from its R&D labs in California, US. Services include cell line development, upstream and downstream development, protein science, and antibody discovery. The biologics manufacturing facility at Bengaluru will complement these services and will enable GMP and non-GMP manufacturing. It will have advanced single-use bioreactors with capacities ranging from 50 Ltr to 2000 Ltrs and will offer integrated solutions including process development, process validation, analytical development, small-scale manufacturing, large-scale DS manufacturing and stability services.
